Product Code Database
Biotie Therapies Oyj was a Finland biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and Inflammation and fibrosis liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.
The company has partnering agreements with Lundbeck and UCB. Biotie Therapies Oyj Company Description Business Week
In January 2016, Acorda Therapeutics acquired Biotie Therapies for $363 million.
| Selincro (nalmefene) | alcohol dependence | Lundbeck | EU marketing authorization received | |
| Tozadenant SYN115 | Parkinson's disease | UCB | Phase III clinical trials to start 2015 | |
| VAP-1 antibody | inflammatory diseases | - | Phase I clinical trials ready, seeking partner | |
| SYN120 | AD, cognitive disorders | - | Phase I clinical trials ready, seeking partner | |
| Nepicastat SYN117 | PTSD, cocaine dependency | NIDA | PTSD: Phase II clinical trials, results Cocaine dependency: Phase II clinical trials, in progress | |
| Ronomilast | COPD | - | Phase I clinical trials ready, seeking partner | |
| Nitisinone SYN118 | Movement disorder | UCB | Phase II clinical trials, terminated [2] Stock Exchange release 23 November 2011 | |
| Sources: | ||||
Studies have shown, that nalmefene has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five units of alcohol. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company, this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time. Lundbeck announces start of new phase III clinical trials with nalmefene STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m Balanced CNS and inflammation product pipeline Company website 2008-03-15
In January 2016, the company was acquired by Acorda Therapeutics, for . In November 2017, the company announced discontinuation of the agent following the death of 5 patients enrolled in the tozadenant Phase III trial from agranulocytosis and associated severe adverse events possibly related to tozadenant.
|
|
